We tested one LIN28 inhibitor, 1632, which was demonstrated to have in vivo preclinical efficacy in LIN28B‐overexpressing subtypes of Ewing sarcoma and in oral squamous cell carcinoma [29, 30]. Here, LIN28A is linked to oral cavity squamous cell carcinoma.